Genetic Test Evaluation

understanding how genetic tests impact patient management

Oncofocus (Oncologica)

August 18, 2016

Cancer is the second most common cause of death in the United States. There will be an estimated 1,685,210 new cancer cases diagnosed and 595,690 cancer deaths in 2016 (ACS, 2016). Molecular tumor biopsy profiling aims to identify actionable genetic alterations in cancer genes to aid treatment recommendations. This report focuses on the Oncologica Oncofocus Test, a next-generation sequencing (NGS) assay that examines 175 genes, including 2470 coding variants, 281 gene fusions, and 19 genes susceptible to copy number variations, to identify treatment options based on actionable  genomic alterations. According to Oncologica, the Oncofocus Test is intended for solid tumor patients with advanced or early-stage cancer, patients with rare tumors or cancers of unknown origins, or patients who have developed treatment resistance.